Work

1802Prevalence of KPC-possessing Klebsiella pneumoniae in New York City: Have We Turned the Corner?

Year: 2014

Type: article

Abstract: Background. Klebsiella pneumoniae carrying the carbapenemase KPC have become established in medical centers in New York City. At the height of the problem in 2006, over one third of K. pneumoniae isolates were found to be carrying this beta-lactamase. Methods. A three month surveillance study was conducted from November 2013-January 2014 involving 11 hospitals in New York City. All unique patient isolates of K. pneumoniae were gathered from hospital microbiology laboratories. Susceptibility testing was performed by the agar dilution method according to CLSI methods. Cephalosporin-resistant isolates were screened by PCR for the presence of blaKPC. Rates of K. pneumoniae positive for blaKPC were compared to similar surveillance studies conducted in 2006 and 2009 for nine hospitals in Brooklyn, NY. Rates of KPC-possessing isolates from 2006 and 2013-2014 were compared by Fishers' exact test. Results. A total of 944 isolates of K. pneumoniae were collected in the 2013-2014 surveillance study. Overall susceptibility rates include: 68% to ceftazidime, 80% to piperacillin-tazobactam, and 86% to meropenem. Of the 944 isolates, 125 (13%) were found to be carrying blaKPC. Nine hospitals participated in similar surveillance studies conducted in 2006 and 2009. The percentages of KPC-possessing isolates for the nine hospitals during the three surveillance studies are given in the table. Conclusion. Since the height of the problem in 2006, steady and significant progress has been made in reducing the rates of blaKPC-carrying K. pneumoniae in most hospitals in Brooklyn, NY. However, some hospitals continue to struggle with this pathogen. Disclosures. C. Urban, Pfizer: Speaker's Bureau, Speaker honorarium; Cubist: Speaker's Bureau, Speaker honorarium D. Landman, Tetraphase: Research Contractor, Research grant; Achaogen: Research Contractor, Research grant J. Quale, Tetraphase: Research Contractor, Research grant; Achaogen: Research Contractor, Research grant

Source: Open Forum Infectious Diseases

DOI: 10.1093/ofid/ofu051.174